Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mani

Showing results (131-140 of 169) with videos related to

Pageof 17
Sort By:
Cell|October 14, 2022
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASHMasaki Kimura, Takuma Iguchi, Kentaro Iwasawa, et al.
Gut|August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 30, 2018
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic SteatohepatitisEric J Lawitz, Angie Coste, Fred Poordad, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Journal of Hepatology|August 23, 2016
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised studyScott Fung, Peter Kwan, Milotka Fabri, et al.
Gastroenterology|September 28, 2014
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label studyMichael P Curry, Xavier Forns, Raymond T Chung, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
Pageof 17

Showing results (131-140 of 169) with videos related to

Sort By:
Pageof 17
Cell|October 14, 2022
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASHMasaki Kimura, Takuma Iguchi, Kentaro Iwasawa, et al.
Gut|August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 30, 2018
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic SteatohepatitisEric J Lawitz, Angie Coste, Fred Poordad, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Journal of Hepatology|August 23, 2016
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised studyScott Fung, Peter Kwan, Milotka Fabri, et al.
Gastroenterology|September 28, 2014
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label studyMichael P Curry, Xavier Forns, Raymond T Chung, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
Pageof 17